Evidence map›Paper›PMID 41814009›Full record

ArticleWorld journal of urology2026

The utility of pelvic lymph node dissection in PSMA-PET negative intermediate and high-risk prostate cancer patients undergoing radical prostatectomy.

Giuseppe Reitano, R Jeffrey Karnes, Giacomo Novara, Daniel S Roberson, Mohamed E Ahmed, Filippo Carletti, Umar Ghaffar, Giuseppe Dinoi, Salvatore Carrozza, Maurizio Bentivoglio and 5 more

Abstract readComparative Study
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. From reflex to reason: rethinking pelvic lymph node dissection in the PSMA PET Era.European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Giuseppe ReitanoDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, 55905, Rochester, MN, USA.
Giacomo NovaraDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.
Daniel S RobersonDepartment of Urology, Mayo Clinic, 55905, Rochester, MN, USA.
Mohamed E AhmedDepartment of Urology, Mayo Clinic, 55905, Rochester, MN, USA.
Filippo CarlettiDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.
Umar GhaffarDepartment of Urology, Mayo Clinic, 55905, Rochester, MN, USA.
Giuseppe DinoiDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.
Salvatore CarrozzaDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.
Maurizio BentivoglioDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.
Simone BottiDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.
Carlo PrevatoDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.
Giovanni BettoUrology Unit, Azienda Ospedale Università Padova, 35126, Padova, PD, Italy.
Fabio ZattoniDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy. fabio.zattoni@unipd.it.ORCID http://orcid.org/0000-0002-4178-373X
Fabrizio Dal MoroDepartment of Surgery, Oncology and Gastroenterology, Università Padova, 35128, Padova, PD, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare perioperative and early oncological outcomes of robotic radical prostatectomy (RP) with and without extended pelvic lymph node dissection (PLND) in a cohort of intermediate (IR)-to-high-risk (HR) prostate cancer (PCa) patients.

methodsData was prospectively collected from 88 patients (47 PLND, 41 no-PLND) with unfavorable intermediate- and high-risk miN0M0 PCa, all staged preoperatively with PSMA-PET/CT. Outcomes were assessed using Kaplan-Meier curves, uni-and multivariable Cox regression, for biochemical recurrence-free survival (BCRFS) and biochemical failure-free survival (BCFFS). A propensity score matched analysis with Cox regression was undertaken matching 1:1 for potential confounders (age, iPSA, preoperative ISUP, cT stage at MRI).

resultsBoth groups (PLND and no-PLND) had the same proportion of HR patients (p = 1.0). The no-PLND group had a shorter median operative time by 50 min (p < 0.01). Conversely, the PLND group experienced significantly higher rates of 90-day high-grade complications (p = 0.03) and lymphoceles (p < 0.01). Over a median 20.5-month follow-up, no significant differences emerged in BCRFS (p = 0.59) or BCFFS (p = 0.76). Uni- and multivariable analyses adjusted for UCSF CAPRA and CAPRA-S variables, as well as propensity score matching, confirmed PLND was not associated with improved BCFFS. In patients who did recur, the sites of recurrence did not differ between the two groups (p = 0.62), with pelvic nodal recurrence being the most common site of recurrence in both groups (6, 50% for PLND and 3, 60% for no-PLND).

conclusionsIn this short-term follow-up, performing PLND increased high-grade postoperative complications without providing a clear early oncological benefit regarding BCRFS, PSA persistence, or recurrence location.

Indexed as

Lymph Node ExcisionPositron Emission Tomography Computed TomographyProstatectomyProstatic NeoplasmsAgedAntigens, SurfaceGlutamate Carboxypeptidase IIHumansMaleMiddle AgedPelvisProspective StudiesRisk AssessmentRobotic Surgical ProceduresAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIBiochemical recurrenceLymph node dissectionProstate cancerPSMA-PET

Identifiers

PMID41814009
PMCPMC12979355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.